5245582022-04-012022-06-305245582022-04-012022-06-30in-bse-fin:OtherExpenses1Member5245582022-04-012022-06-30in-bse-fin:OtherExpenses2Member5245582022-04-012022-06-30

ItemsThatWillNotBeReclassifiedToProfitAndLoss1

5245582022-04-012022-06-30

ItemsThatWillNotBeReclassifiedToProfitAndLoss2

5245582022-04-012022-06-30

ItemsThatWillBeReclassifiedToProfitAndLoss1

iso4217:INRiso4217:INRxbrli:shares

524558

NEULANDLAB

NOTLISTED

INE794A01010

NEULAND LABORATORIES LIMITED

Equity

2022-04-01

2023-03-31

2022-08-03

2022-07-11

INR

Lakhs

First quarter

Single segment

Manufacturing of Active Pharmaceutical Ingredients

2022-08-03

11:40:00

2022-08-03

13:20:00

Not applicable

2022-04-01

2022-06-30

Unaudited

Consolidated

2211699000

5118000

2216817000

962468000

-76139000

482997000

28581000

127993000

556326000

2082226000

134591000

41001000

-6068000

34933000

99658000

5692000

105350000

129005000

7.77

1. The financial results for the quarter ended 30 June 2022 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 3rd August 2022. 2. The financial results have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 3. The Consolidated Financial Results include results of the following wholly owned subsidiaries: (a) Neuland Laboratories Inc., USA; (b) Neuland Laboratories KK., Japan. 4. The operations of the Company and its subsidiaries are predominantly related to the manufacture and sale of active pharmaceutical ingredients and allied services. As such there is only one primary reportable segment as per Ind AS 108 "Operating Segments". 5. The EPS for quarters has not been annualised. 6. The figures for the quarter ended 31st March, 2022 are the balancing figures between the audited figures in respect of the full financial year and the published figures upto nine months of the relevant financial year. 7. The previous period figures have been regrouped/rearranged wherever necessary to make it comparable with the current period.

Manufacturing expenses

308567000

Other expenses

247759000

Re-measurement gains/losses on defined benefit plans

6613000

Equity instruments through other comprehensive income

-151000

6462000

1664000

Exchange differences in translating the financial statements of a foreign operations

894000